Table 3.
Ongoing clinical trials of VEGF-targeted therapy in UC
| Drugs | Targets | Combinations | Conditions | Phase | NCT |
|---|---|---|---|---|---|
| Bevacizumab | VEGF | MK-7684A | UC | II | NCT05007106 |
| Bevacizumab | VEGF | Dasatinib | Met/Adv UC | I | NCT04164069 |
| Lenvatinib | VEGFR1–3 | GI-101 | Met/Adv UC | I/II | NCT04977453 |
| Lenvatinib | VEGFR1–3 | MK-7684A | UC | II | NCT05007106 |
| Ramucirumab | VEGFR2 | TRK-950 | UC | I | NCT03872947 |
VEGF: vascular endothelial growth factor; UC: urothelial carcinoma; VEGFR1–3: vascular endothelial growth factor receptor 1–3; Adv: advanced; Met: metastatic; MK-7684A: the combination of vibostolimab and pembrolizumab; GI: SIM0323